Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, HC Wainwright assumed coverage on shares of Capricor Therapeutics in a research report on Wednesday, July 6th. They issued a “buy” rating and a $13.00 price objective on the stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Capricor Therapeutics (OTCMKTS:CAPR) traded up 2.99% during trading on Tuesday, reaching $3.45. 46,475 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $3.54 and a 200 day moving average price of $3.62. Capricor Therapeutics has a 52 week low of $1.88 and a 52 week high of $5.40. The firm’s market capitalization is $61.94 million.

Capricor Therapeutics (OTCMKTS:CAPR) last announced its earnings results on Monday, August 15th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.02. Equities research analysts forecast that Capricor Therapeutics will post ($1.04) earnings per share for the current fiscal year.

In other Capricor Therapeutics news, major shareholder Sinai Medical Center Cedars acquired 312,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 21st. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $1,000,000.00. Following the transaction, the insider now directly owns 2,904,798 shares of the company’s stock, valued at $9,295,353.60. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

A hedge fund recently raised its stake in Capricor Therapeutics stock. Vanguard Group Inc. increased its position in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 25.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,975 shares of the company’s stock after buying an additional 5,704 shares during the period. Vanguard Group Inc. owned approximately 0.16% of Capricor Therapeutics worth $111,000 at the end of the most recent quarter.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with's FREE daily email newsletter.